Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s):  AQSZF

Healthcare
Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.


TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(325)
•••
Comment by Actuarialon Mar 20, 2017 9:45am
85 Views
Post# 26001388

RE:AQS (MC $20M) Undiscovered and terrible Undervalued Stock

RE:AQS (MC $20M) Undiscovered and terrible Undervalued StockBiosyent (RX.V) 2016 revenue $18M, 14,403,553 common shares issued and outstanding, market cap $109.47M. AQS 2016 revenue $534.73K, 88M common shares issued and outstanding, market cap $19.64M. AQS have the potential similar to Biosyent? I doubt about it ......
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities